When it comes to maintaining clean equipment for making medicines, one drug maker recently danced around the issue.

During an inspection of a Centurion Laboratories facility in India last October, a Food and Drug Administration investigator noticed a variety of troubling manufacturing problems. These included a failure to follow written procedures for cleaning and maintaining equipment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Then they are out of compliance with Part 11 along with the common sense items that they overlooked as well.

  • At least the company did not truly ‘dance around the truth’ when it came to the cleaning issues. The forms torn to “avoid confusing the investigator,” perhaps not so much?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy